Comprehensive Gene Profiling (CGP): Moving Beyond Single-Gene Testing in Modern Oncology

Precision oncology has evolved rapidly over the past decade, shifting from isolated single-gene assays toward broader, more integrated molecular strategies. Comprehensive Gene Profiling (CGP) reflects this shift by enabling simultaneous assessment of a wide range of genomic alterations—including single nucleotide variants (SNVs), insertions and deletions, copy number variations (CNVs), and gene fusions—from a single test.

Compared with sequential single-gene testing, CGP provides a more complete view of tumor biology. This is increasingly important as treatment decisions now depend on multiple biomarkers rather than a single molecular alteration. In many advanced cancers, clinically relevant targets may be uncommon or unexpected, and narrow testing strategies risk missing actionable findings that could meaningfully alter management.

Importantly, modern CGP approaches integrate both DNA and RNA analysis. While DNA sequencing identifies mutations and copy number changes, RNA-based testing improves detection of gene fusions and splice variants that may be poorly captured at the DNA level alone. Together, these strategies increase diagnostic sensitivity and reduce false-negative results, particularly in tumors driven by transcriptional alterations.

Clinical & Operational Relevance

From a real-world oncology perspective, CGP supports more efficient and informed decision-making:

• Broader detection of actionable alterations, including rare mutations and oncogenic fusions

• Improved therapy selection, aligning patients with approved targeted treatments or immunotherapies

• Enhanced clinical trial matching, especially for biomarker-driven studies

• Reduced tissue consumption, minimizing the need for repeated biopsies

• Streamlined workflows, replacing multiple sequential tests with a single integrated assay

CGP is most impactful when considered early in the patient journey—particularly at diagnosis of advanced or metastatic disease—where molecular insights can guide first-line or early-line treatment strategies rather than being deferred until later stages.

As oncology becomes increasingly biomarker-driven, the value of Comprehensive Gene Profiling lies not in testing more genes, but in delivering the right genomic information at the right time to support better clinical decisions.

---

AGTC Genomics Perspective

At AGTC Genomics, Comprehensive Gene Profiling is positioned as a clinical enabler rather than a standalone test. By integrating DNA and RNA-based NGS, robust bioinformatics, and clinically focused interpretation, CGP is designed to support oncologists with actionable, evidence-aligned insights that fit into real-world practice. Emphasis is placed on test quality, turnaround time, and regional relevance to ensure results are both reliable and clinically meaningful.